Post Reply
4501-4520 of 4753
Do self a service Watch Glued Closely as it&rsquo s
otw . .. cumming !
otw . .. cumming !
🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍 🍍
Healthcare stocks get a shot in the arm as Wuhan virus fears rise
The outbreak of a new SARS-like virus originating in Wuhan, the capital of China&rsquo s Hubei province, is putting Asian stock markets on edge.
By Jan 21, four people have died from the virus, as 15 Chinese medical workers were reported to have been infected after treating infected patients.
The World Health Organization has confirmed that the pathogen, known as 2019-nCoV, is being transmitted among humans.
It had been originally hoped that transmission of the virus was limited from animals to humans, as some of the first patients worked or shopped at a seafood market in Wuhan where live animals and wildlife parts were also reportedly sold.
&ldquo The outbreak of a SARS-like coronavirus in Wuhan is developing into a major potential economic risk to the Asia-Pacific region now that there is medical evidence of human-to-human transmission,&rdquo says Rajiv Biswas, chief economist for Asia Pacific at IHS Markit.
&ldquo With a number of Wuhan virus cases having already been detected outside of China, this outbreak is particularly concerning just as the Chinese New Year season gets underway, with millions of Chinese tourists travelling both within China and to many popular Asian tourist destinations, such as Thailand, Vietnam, Japan, Singapore and South Korea,&rdquo he adds.
Already, confirmed coronavirus cases have been identified in Thailand, Japan and South Korea.
&ldquo Asia will remember back to the origins of SARS outbreak and its adverse effects on economic activity in the region. It is, therefore, no surprise that both equities and oil are being marked lower across Asia today,&rdquo says Jeffrey Halley, senior market analyst for Asia Pacific at OANDA.
The way Halley sees it, the price action in Asia is &ldquo a window to the future&rdquo if the pneumonia outbreak escalates. &ldquo We would expect Asian equities, currencies, and also energy, to all come under pressure on lower growth fears for the region,&rdquo he adds.
In contrast, fears of the spread of the Wuhan virus is giving some healthcare stocks a shot in the arm.
Healthcare names were the best performers in the MSCI China Index on Monday, with the sector rising 1.3%. Antibiotics makers Jiangsu Lianhuan Pharmaceutical Co, Shandong Lukang Pharmaceutical Co and Shenzhen Neptunus Bioengineering Co all climbed the 10% daily limit.
In Singapore, Healthway Medical Corporation, the private outpatient medical service provider with more than 80 clinics across the island, led the way on Tuesday, surging 42.9% to a new 52-week-high of 4 cents as at 12pm.
Shares in Medtecs International Corporation, the manufacturer and distributor of medical consumables for the healthcare industry, also ascended to a 52-week peak, jumping 26.9% to 6.6 cents as at 12 pm.
Meanwhile, AsiaMedic, a healthcare provider that focuses on the management of clinical services in the fields of disease prevention, early illness detection and advanced diagnostics, soared 23.1% to 1.6 cents.
Other healthcare counters, including Clearbridge Health, Singapore Medical Group, UG Healthcare Corporation, and Thomson Medical Group, were also among the biggest climbers for the day &ndash rising 5.2%, 5.0%, 3.7%, and 3.2%, respectively.
Apart from the healthcare sector, however, IHS Markit&rsquo s Biswas warns that some other sectors of the economy could be &ldquo particularly vulnerable&rdquo to a SARS-like virus epidemic that can be spread by human-to-human transmission. These include retail stores, restaurants, conferences, sporting events, tourism and commercial aviation, he says.
&ldquo A key concern is the potential risk for the Tokyo Summer Olympics in July-August 2020,&rdquo Biswas adds. &ldquo Therefore, containing the current Wuhan virus outbreak has become a key priority for Chinese and international health care authorities, with enhanced screening of travellers now being put into place in many major airports worldwide.&rdquo
can see some rotation into other med stocks like this one
Global health industry&rsquo s $1t war chest to drive 2020 deal boom: EY
https://www.dealstreetasia.com/stories/health-industry-2020-deal-boom-ey-170140/?mc_cid=468d0b2627& mc_eid=62c70c6de8
The health industry&rsquo s more than $1 trillion in &ldquo firepower&rdquo should deliver another strong year for deals, a new report shows. Big biotechnology firms and their medical technology brethren will be active dealmakers in 2020 as companies look to fuel needed growth, according to a report released Monday by professional services firm EY. Cell and gene therapy firms are expected to continue to dominate biotech deals. EY sees the potential for almost $300 billion in deals even without a repeat of 2019&rsquo s mega-mergers.
&ldquo To continue the record-setting M& A trajectory, companies outside big pharma must return to the dealmaking table and make transformative bets of their own,&rdquo analysts led by Pamela Spence and Peter Behner wrote. Their findings suggest that most of the largest biopharma companies have the ability to do bolt-on deals with about one-third having the capacity for mega-mergers, defined as transformative deals with valuations of at least $40 billion for biopharma and $10 billion for medtech.
The report comes just hours before the annual JPMorgan Healthcare Conference kicks off in San Francisco. The event has long been a top spot for companies to showcase new deals and for executives to rub elbows with bankers and lawyers. In a September survey, 94% of respondents told EY that they expect deals to either increase or stay flat over the next year. The normal benchmark for biotech and medical technology deals since 2015 is about $200 billion a year.
&ldquo Firepower remains plentiful and we expect to see more activity in medtech and big biotech, with mega-mergers coming from companies with acute growth gaps,&rdquo Behner said in a statement. &ldquo Market volatility and the desire to deepen therapeutic focus will continue to be deal catalysts in 2020.&rdquo The firm defines &ldquo firepower&rdquo as a company&rsquo s capacity to fund deals, including its cash, existing debt, debt capacity and market valuation.
Large biotech companies have historically preferred to return cash to investors via share buybacks rather than deals. Share repurchases and research and development accounted for roughly 80% of their spending in 2019 compared to just 9% on mergers and acquisitions.
https://www.dealstreetasia.com/stories/health-industry-2020-deal-boom-ey-170140/?mc_cid=468d0b2627& mc_eid=62c70c6de8
The health industry&rsquo s more than $1 trillion in &ldquo firepower&rdquo should deliver another strong year for deals, a new report shows. Big biotechnology firms and their medical technology brethren will be active dealmakers in 2020 as companies look to fuel needed growth, according to a report released Monday by professional services firm EY. Cell and gene therapy firms are expected to continue to dominate biotech deals. EY sees the potential for almost $300 billion in deals even without a repeat of 2019&rsquo s mega-mergers.
&ldquo To continue the record-setting M& A trajectory, companies outside big pharma must return to the dealmaking table and make transformative bets of their own,&rdquo analysts led by Pamela Spence and Peter Behner wrote. Their findings suggest that most of the largest biopharma companies have the ability to do bolt-on deals with about one-third having the capacity for mega-mergers, defined as transformative deals with valuations of at least $40 billion for biopharma and $10 billion for medtech.
The report comes just hours before the annual JPMorgan Healthcare Conference kicks off in San Francisco. The event has long been a top spot for companies to showcase new deals and for executives to rub elbows with bankers and lawyers. In a September survey, 94% of respondents told EY that they expect deals to either increase or stay flat over the next year. The normal benchmark for biotech and medical technology deals since 2015 is about $200 billion a year.
&ldquo Firepower remains plentiful and we expect to see more activity in medtech and big biotech, with mega-mergers coming from companies with acute growth gaps,&rdquo Behner said in a statement. &ldquo Market volatility and the desire to deepen therapeutic focus will continue to be deal catalysts in 2020.&rdquo The firm defines &ldquo firepower&rdquo as a company&rsquo s capacity to fund deals, including its cash, existing debt, debt capacity and market valuation.
Large biotech companies have historically preferred to return cash to investors via share buybacks rather than deals. Share repurchases and research and development accounted for roughly 80% of their spending in 2019 compared to just 9% on mergers and acquisitions.
CBH has entered the fast-growing healthcare markets in Indonesia and the Philippines through two acquisitions.
http://www.hnworth.com/article/invest/brokers-picks/clearbridge-health-limited/
Both countries rank among the lowest in Asia in terms of the number of hospital beds and health professionals per capita. Healthcare spending in both countries has been growing at around 9 &ndash 10% p.a. A key feature of its new Indonesian business is recurring revenue. Renal dialysis is a lifetime treatment, and CBH expanded from 15 hospitals at acquisition to 21 currently and another 13 under renovation. CBH acquires asset-light, fast-growing healthcare segments. After the acquisition, CBH grows the businesses through expansion in capacity, network and capabilities. Maintain BUY with an unchanged target price of S$0.26. We used DCF valuation to capture the full benefit of CBH impressive growth over the next five years.
Closing Price: S$0.14
http://www.hnworth.com/article/invest/brokers-picks/clearbridge-health-limited/
Both countries rank among the lowest in Asia in terms of the number of hospital beds and health professionals per capita. Healthcare spending in both countries has been growing at around 9 &ndash 10% p.a. A key feature of its new Indonesian business is recurring revenue. Renal dialysis is a lifetime treatment, and CBH expanded from 15 hospitals at acquisition to 21 currently and another 13 under renovation. CBH acquires asset-light, fast-growing healthcare segments. After the acquisition, CBH grows the businesses through expansion in capacity, network and capabilities. Maintain BUY with an unchanged target price of S$0.26. We used DCF valuation to capture the full benefit of CBH impressive growth over the next five years.
Closing Price: S$0.14
Clearbridge serves close to 4 million patients per year with a Public-Private-Partnership Model in Indonesia
Adopting a Public-Private-Partnership Model to scale its healthcare services operations in Indonesia, Clearbridge currently manages a total of 49 hospital joint operation contracts (&ldquo JOs&rdquo ) in Indonesia serving close to 4 million patients per year, primarily in the area of renal care (through PT Tirta Medika Jaya (&ldquo TMJ&rdquo ) which was acquired in April 2018) and pathology (through PT Indo Genesis Medika (&ldquo IGM Labs&rdquo ) which was acquired in May 2019) at public and private hospitals (ranging from Class A to Class C) in Indonesia.
The renal care services and laboratory testing services offered by TMJ and IGM Labs are reimbursed through the Indonesia health coverage program.
TMJ is currently operating 21 renal care centres under JO with hospitals in Indonesia. In addition, there are another 16 renal care centres that are currently under construction, with the potential of revenue contribution once they are completed progressively.
For IGM Labs, it is operating 12 diagnostics laboratories with another JO Contract that is in the process of being novated to IGM Labs. Undertaking more than 7 million pathology tests a year, IGM Labs has diagnostics laboratories in 6 of the largest Class A hospitals, out of 16 Class A hospitals in Indonesia.
To promote the adoption of precision medicine in Indonesia, the Group will be introducing healthcare solutions and technologies from its medical technologies companies into these JOs.
- Revenue increased by more than 2 folds in 3Q2019 with the contributions from the acquisitions of IGM Labs and nine dental clinics that were completed in May 2019 and August 2019 respectively
- Validating the Group&rsquo s EBITDA-focused strategy, the Group&rsquo s 3Q2019 revenue of S$6.39 million is almost on par with its first half revenue of S$6.85 million
- As of 30 September 2019, the Group&rsquo s financial position remained healthy with total assets increasing to S$99.92 million with cash at banks and short-term deposits of S$15.10 million.
Another showcase of the potential of precision medicine..
Chinese parents test DNA to check if kids will become prodigies
https://www.straitstimes.com/asia/east-asia/chinese-parents-test-dna-to-check-if-kids-will-become-prodigies
Positive EBITDA but still lmaking losses.. isit a good or bad thing? the report also did not mentioned a thing about whether their business is affected by the hk riot... or did i missed it...
WBdisciple ( Date: 14-Nov-2019 19:05) Posted:
|
Clearbridge Continues its Strong Growth Momentum Quarterly Revenue Jumps 211.5% to a Record S$6.39 Million in 3Q2019
https://links.sgx.com/1.0.0/corporate-anno...
&bull Revenue increased by more than 2 folds in 3Q2019 with the contributions from the acquisitions of IGM Labs and nine dental clinics that were completed in May 2019 and August 2019 respectively
&bull Validating the Group&rsquo s EBITDA-focused strategy, the Group&rsquo s 3Q2019 revenue of S$6.39 million is almost on par with its first half revenue of S$6.85 million
&bull Excluding fair value losses in associate and derivative financial instruments & non-recurring operating expenses, the Group has recorded positive EBITDA of S$0.38 million in 3Q2019
It is worth noting that the fair value losses related to associate and derivative financial instruments are non-cash components.
As of 30 September 2019, the Group&rsquo s financial position remained healthy with total assets increasing to S$99.92 million with cash at banks and short-term deposits of S$15.10 million.
Commenting on the 3Q2019 results, Mr Jeremy Yee (余 斌 ), Executive Director and Chief Executive Officer of Clearbridge, said, &ldquo Our record revenue achieved in this quarter reinforces the coherence of our EBITDA-focused business strategy and strong operational execution.
We have made substantial progress in the execution of our strategic priorities to build unique value propositions in high-growth healthcare segments in Asia.
With our strategic focus in precision medicine, 2019 will be another step forward in our commitment to deliver sustainable profitable growth.&rdquo
Closed at today's HAI coupled with heavy volume. Hopefully got something goose. Best tmr gap up above fivety .
why so quiet here. party just started
383838 ( Date: 14-Nov-2019 17:08) Posted:
|
Wanau eh! This bridge today so strong n done so much. Shiok man. In out in out shiok man. In 41 out 47. In 44 again. But havent out. Tmr lah. Hehehehehe!!!!!!!
still a seed. dont wait for leaf to appear and chase
383838 ( Date: 14-Nov-2019 09:40) Posted:
|
This bridge is coming
3 Cancer Treatment Stocks to Buy Right Now
The Motley Fool
Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening.
Let' s see how Mirati Therapeutics (NASDAQ: MRTX), Iovance Biotherapeutics (NASDAQ: IOVA), and Personalis (NASDAQ: PSNL) are all using gene therapy in the fight against cancer.
1. Using genetic research to inhibit the genes responsible for cancer growth
Mirati Therapeutics is in a race with Amgen (NASDAQ: AMGN) to find a drug that successfully inhibits KRAS mutations. KRAS is a gene in our bodies that has been identified as a cause of multiple cancers. Right now one of Mirati' s drugs is targeting a specific sub-mutation identified as KRAS G12C. This genetic malfunction is seen in 14% of non-small cell lung cancers, 5% of colon cancers, and 2% of pancreatic cancers. The company' s drug is an attempt to shut down this mutated gene so it will stop producing cancer cells.
Investors who want to play it safe might want to invest in Amgen, not Mirati Amgen is also pursuing drugs to inhibit the KRAS mutations. However, Amgen is a highly profitable, $130 billion megacap biotech with multiple drugs in clinical trials. If its KRAS program fails, Amgen' s stock will take a minor hit and the company will continue onwards and upwards. On the other hand, if Amgen and Mirati are both right about the importance of KRAS genes, then Mirati shareholders are likely to see far bigger returns on their investments. With the smaller biotech, the risk is higher but the rewards are greater.
Mirati is a $4 billion small cap with extensive knowledge of KRAS. Failure here would be brutal to the stock. On the other hand, any success would boost the stock into the stratosphere. So far, investors in Mirati have been winning big. Amgen has returned 56% to investors over the last five years, slightly underperforming the S& P 500, but tiny Mirati has returned 523%.
2. Using the body' s own immune system to destroy cancers
Iovance Biotherapeutics is introducing a novel way to fight against cancer. The company relies upon medicine that is specialized for each patient. When a cancer starts attacking your body, your system starts producing lymphocytes that are designed to infiltrate and attack the tumor. Cancer cells adopt and mutate to avoid destruction.
What Iovance does is remove some of these cancer-fighting agents, referred to as tumor-infiltrating lymphocytes (TILs), from your body. The company' s technology amplifies and multiplies these cells in the lab, creating billions of them. Then your own cancer-fighting agents are injected back into your body.
Iovance is running a phase 3 trial trial for Lifileucel, its treatment for skin cancer. But what' s causing the most excitement is LN-145, which is being tested on multiple cancers. The company is running a phase 3 trial for cervical cancer, and a phase 2 trial for head and neck cancers. Also, MD Anderson Cancer Network is running a phase 2 test on LN-145 for ovarian cancer and sarcoma.
The stock took off after it was reported that LN-145 had a 44% overall response rate against cervical cancer, and Lifileucel had a 38% overall response rate against melanoma. Iovance is a $2.72 billion small cap. It has $400 million in cash, $12 million in debt, and no revenue. So far in 2019 it' s returned 132% to investors.
3. Mapping 20,000 genes in 775,000 people
Personalis is developing the NeXT platform, a hugely ambitious undertaking that is mapping approximately 20,000 genes in the human body. Spun out of Stanford University, the company has a contract with the U.S. Department of Veterans Affairs. The federal agency is providing it the DNA information of over 775,000 veterans, so with this data, Personalis is mapping over 15 billion human genes. With all these volunteers, it' s developing a massive library of genetic data. Biotechs that subscribe to its service can access this information as they design cancer-fighting drugs in the lab.
The company' s immediate market is all the biotech companies doing cancer research. Using its library, subscribers can find cancer targets and design specific drugs to suppress the mutating genes that spread cancer in human beings. Right now Personalis has over 45 biopharma subscribers to its service. The company estimates this is a $5 billion market opportunity.
Next year Personalis hopes to compete in the $14 billion market of cancer diagnostics. It will offer its own liquid biopsy designed to detect cancer, and compete with Guardant Health (NASDAQ: GH), as well as NantHealth, Grail (a start-up funded in part by Jeff Bezos and Bill Gates), Thrive (a start-up spun out of Johns Hopkins), and others. We don' t yet know how much Personalis will charge for its biopsy, or how successful it will be.
But what we do know is that right now the company is a lot cheaper than its market-leading peer:
COMPANY REVENUE GROWTH P/S RATIO MARKET CAP STOCK PRICE CHANGE SINCE IPO
Guardant Health 181% 32 $6.75 billion 146%
Personalis 79.8% 6 $325 million (65%)
Data source: Bloomberg and Yahoo Finance. P/S = price to sales IPO = initial public offering.
The market appears to be taking a wait-and-see attitude toward Personalis certainly there' s no excitement right now about its shares. That might change when its liquid biopsy is introduced next year.
In the meantime, Personalis is developing a very impressive library of knowledge of the human genome. Maybe one day the company will be competing with 23andme to provide personalized medicine to individuals (a market estimated to be worth $40 billion). It' s definitely a stock to keep an eye on, as the future looks bright.
Taylor Carmichael owns shares of Iovance Biotherapeutics. The Motley Fool owns shares of and recommends Guardant Health. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO
Tot Biopharm, a Chinese clinical-stage biopharma firm specialized in innovative oncology drugs and therapies, has raised about $75.2 million in an initial public offering (IPO) on the main board of the Hong Kong stock exchange on Friday. The biopharma company offered 90 million shares at a price of HK$6.55 apiece, the lower end of the proposed price range between HK$7.55 and HK$6.55.
Taipei Exchange-listed oral pharmaceutical business Centerlab, Vivo Capital, which invests in the healthcare industry in China and the United States, and Nien Hsing BVI, a wholly-owned subsidiary of Taiwan-based Nien Hsing Textile, served as cornerstone investors subscribing to $20 million worth shares in the IPO.
The listing came about six months after the Suzhou-based Tot Biopharm filed a prospectus with the stock exchange in early May 2019. The company applied to float shares in Hong Kong under rules that allow the listing of pre-profit biotech companies &ndash a new regime that came into effect on April 30, 2018 as authorities of the global financial hub seek to capitalize on opportunities from the up-and-coming biotech firms, which make up a majority of pre-revenue companies seeking an IPO.
The listing reform led to the highest fundraising record on the Hong Kong stock exchange in eight years, reclaiming the city&rsquo s crown as the top 1 IPO market worldwide in 2018 with 125 companies raising $36.5 billion in the year, according to Refinitiv data. Tot Biopharm, founded in 2009, recorded accumulated losses of 753.8 million yuan ($108 million) in 2018, up 55.3 per cent from 485.5 million yuan ($70 million) in 2017, according to its prospectus. The losses further increased by 13.6 per cent to 856.1 million yuan ($123 million) as of April 30, 2019, primarily attributable to increases in research and development expenses in relation to the clinical trials and pre-clinical development of drug candidates.
Tot Biopharm&rsquo s portfolio includes monoclonal antibodies, antibody-drug conjugates, oncolytic virus products and speciality oncology drugs such as liposome drugs, targeting various types of cancers. Its pipeline consists of seven biological and five chemical drug candidates, 11 of which are in-house developed. At present, four biological drug candidates of Tot Biopharm are in the clinical stage. TAB008, the core product of Tot Biopharm, is an anti-VEGF mAb and biosimilar drug candidate to bevacizumab, a medication used for the treatment of a number of cancers. The product will serve the Chinese bevacizumab market, which is projected to grow to 13.1 billion yuan ($1.88 billion) in 2023 with a compound annual growth rate (CAGR) of 32.7%, according to Frost & Sullivan. TAB008 is undergoing Phase III clinical trials in China, and is expected to be launched between the end of 2020 and early 2021, subject to regulatory approval. The company plans to use the net proceeds from the IPO to conduct clinical trials on drug candidates, and to expand sales and marketing staff in preparation for their approval and commercialization. Tot Biopharm has so far raised a total of $108 million across two funding rounds. It raised $6 million in a Series A round led by Chengwei Capital in 2010 and another $102 million in a Series B round in 2018, co-led by 99Fund and China Universal.
Tot Biopharm, a Chinese clinical-stage biopharma firm specialized in innovative oncology drugs and therapies, has raised about $75.2 million in an initial public offering (IPO) on the main board of the Hong Kong stock exchange on Friday. The biopharma company offered 90 million shares at a price of HK$6.55 apiece, the lower end of the proposed price range between HK$7.55 and HK$6.55.
Taipei Exchange-listed oral pharmaceutical business Centerlab, Vivo Capital, which invests in the healthcare industry in China and the United States, and Nien Hsing BVI, a wholly-owned subsidiary of Taiwan-based Nien Hsing Textile, served as cornerstone investors subscribing to $20 million worth shares in the IPO.
The listing came about six months after the Suzhou-based Tot Biopharm filed a prospectus with the stock exchange in early May 2019. The company applied to float shares in Hong Kong under rules that allow the listing of pre-profit biotech companies &ndash a new regime that came into effect on April 30, 2018 as authorities of the global financial hub seek to capitalize on opportunities from the up-and-coming biotech firms, which make up a majority of pre-revenue companies seeking an IPO.
The listing reform led to the highest fundraising record on the Hong Kong stock exchange in eight years, reclaiming the city&rsquo s crown as the top 1 IPO market worldwide in 2018 with 125 companies raising $36.5 billion in the year, according to Refinitiv data. Tot Biopharm, founded in 2009, recorded accumulated losses of 753.8 million yuan ($108 million) in 2018, up 55.3 per cent from 485.5 million yuan ($70 million) in 2017, according to its prospectus. The losses further increased by 13.6 per cent to 856.1 million yuan ($123 million) as of April 30, 2019, primarily attributable to increases in research and development expenses in relation to the clinical trials and pre-clinical development of drug candidates.
Tot Biopharm&rsquo s portfolio includes monoclonal antibodies, antibody-drug conjugates, oncolytic virus products and speciality oncology drugs such as liposome drugs, targeting various types of cancers. Its pipeline consists of seven biological and five chemical drug candidates, 11 of which are in-house developed. At present, four biological drug candidates of Tot Biopharm are in the clinical stage. TAB008, the core product of Tot Biopharm, is an anti-VEGF mAb and biosimilar drug candidate to bevacizumab, a medication used for the treatment of a number of cancers. The product will serve the Chinese bevacizumab market, which is projected to grow to 13.1 billion yuan ($1.88 billion) in 2023 with a compound annual growth rate (CAGR) of 32.7%, according to Frost & Sullivan. TAB008 is undergoing Phase III clinical trials in China, and is expected to be launched between the end of 2020 and early 2021, subject to regulatory approval. The company plans to use the net proceeds from the IPO to conduct clinical trials on drug candidates, and to expand sales and marketing staff in preparation for their approval and commercialization. Tot Biopharm has so far raised a total of $108 million across two funding rounds. It raised $6 million in a Series A round led by Chengwei Capital in 2010 and another $102 million in a Series B round in 2018, co-led by 99Fund and China Universal.
always last to move...
Short term resistance 149, target 159
SgYuan ( Date: 04-Oct-2019 09:08) Posted:
|
Good news for Clearbridge